HBx genetic variability was explored in the Eastern Indian population with low HCC incidence. DNase I sensitive HBV DNA was detected in 53% samples, which differed significantly between clinical groups (P b 0.001). HBV genotypes A (Aa/A1), C (Cs/C1) and D (D1, D2, D3, D5) were detected in 37.5%, 18.7% and 43.7% samples respectively. Population specific signature HBx residues A 36 , V 88 , S 101 in Aa/A1 and residues P 41 , Q 110 in D5 were detected. Mutations T 127 , M 130 and I 131 were detected in 66.7%, 91% and 75% of genotype A, C and D5 samples respectively. Very low occurrence of HCC associated mutations (V 5 M/L, P 38 S, and H 94 Y) and absence of C-terminal deletions were observed. Our study shows that HBV genotype associated clinically important HBx variations may evolve and act distinctly in different geo-ethnic populations. Further studies on HBx functions from the perspective of genetic variability are essential for the better understanding of the clinical significance of HBV.
Introduction
Hepatitis B virus (HBV) infection is a global health problem with more than 2 billion infected individuals. HBV infection leads to diverse outcomes ranging from acute to fatal fulminant hepatitis, and chronic hepatitis (CHB), which may result in severe complications as liver cirrhosis (LC) and hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) is one of the important human DNA viruses having strong oncogenic potential (De Oliveira, 2007) .
Genetic and phylogenetic analysis of HBV DNA sequences has lead to the definition of eight genotypes designated A through H, based on more than an 8% diversity in the whole genome, and further into their subgenotypes (more than 4%, but less than 8% intragenotype diversity), having distinct ethno-geographical distribution (Schaefer, 2005) . Recent studies have clearly demonstrated that genotype variability of different HBV genetic regions can influence the clinical manifestation, and even response to therapy (Schaefer, 2005) .
The highly compact, HBV genome encodes four overlapping ORFs (PreS/S, PreC/C, Pol and X). Considering their clinical significance in diagnostics, immune evasion, vaccine development, immune activation functions and drug resistance, studies on the genetic variability of the PreS/S, PreC/C and Pol genetic regions have remained at the foci of earlier investigation. However, data on the clinical impact of HBx genetic variability is still sparse (Kim et al., 2008) . The X ORF is the smallest, but expresses a 154 amino acid multifunctional molecule (HBx), with an N-terminal negative regulatory/antiapoptotic and a Cterminal proapoptotic/transactivation domain, and has widely been associated with modulation of a wide range of normal cell functions, leading to HCC (Bouchard and Schneider, 2004; Schuster et al., 2002; Tang et al., 2006) . In view of its strong involvement in HBV related pathogenesis, recent genetic analysis studies from our group and others (Datta et al., 2007; Sung et al., 2008) , and in vitro functional analysis studies (Lin et al., 2005; Tan and Chen, 2005) have highlighted the clinical substance of HBx genetic variability. We have earlier demonstrated that HBx genetic variability can enlighten the differential oncogenic potential of HBV genotypes (Datta et al., 2007) .
In India, more than 10% of the global chronic HBV population reside (Sarin et al., 2001) . HBV genotypes A and D are known to circulate in different parts of India (Thakur et al., 2002; Gandhe et al., 2003; Vivekanandan et al., 2004) . In addition to these two genotypes, we have recently documented, characterized and found that HBV genotype C has recently emerged in this part of India and thus has remained confined in the Eastern India population (Datta et al., 2006; Banerjee et al., 2006a Banerjee et al., , 2006b . Based on full-length genome analysis, we have also revealed that HBV genotypes A and C circulating in the eastern part of India are phylogenetically related to HBV strains prevalent in Sub-Saharan Africa and East Asia respectively (Banerjee et al., 2006a) . Interestingly, despite this similarity in circulation of HBV genotypes, the incidence of HCC is very low in India (average annual incidence of ≤3.3 HCC cases/100,000 individuals), compared to Sub-Saharan Africa and East Asian countries (average annual incidence of ≤98.9 HCC cases/100,000 individuals) (Hussain et al., 2007) . Regardless of such an interesting facet of HBV epidemiology, the clinical relevance of the HBx genetic variability of Indian HBV strains has not been sought previously.
The main aim of this study was to investigate the genetic heterogeneity of HBx sequences in our population. We analyzed and compared the HBx sequence from our study population with related GenBank sequences and published literature related to clinically relevant HBx variations. In this manuscript we discuss the clinical significance of the genetic variability of HBx and also present the HBx genetic variability in our study population with interesting HBV epidemiology.
Results

Amplification of X gene
During this study, we observed a discrepancy in amplification results of the surface gene and the X gene region amplification PCR assays, although these assays had similar sensitivity, as calibrated with an international HBV DNA standard (NIBSC code 97/750; National Institute of Biological Standards and Control, Hertfordshire, UK). Of the 102 HBV DNA samples that were positive by partial surface gene PCR (amplifying nts 184 to 731 from the EcoRI site), the HBV genome region corresponding to nts 1092 to 1972 including the entire X gene region could be amplified from a total of only 48 (47%) samples, suggesting the absence of this region in the rest of the samples. Among the rest of the 54 samples in which full-length X gene could not be amplified, our attempts of amplifying partial X gene using previously published primers also failed repeatedly. However the extracts were repeatedly found to be positive for PCR assays amplifying different regions of human genomic DNA and HBV core gene/preC and PreS/S regions, ruling out the possibility of faulty DNA extraction in these samples. Further, false positivity in the surface gene, precore/core gene PCR due to cross contamination was also excluded by the results obtained with controls included during extraction and amplification stages.
Fascinatingly, we observed that full-length X gene could only be amplified in the extracts that had full-length DNase I resistant virion HBV DNA. Such intact virion HBV DNA was detected in a lower but almost similar percentage of the acute hepatitis B (ACU), inactive carriers (IC) and LC patients (37.5%, 34.4% and 33.3% respectively), while the percentage of detection of intact viral genome was significantly higher (P b 0.001) in CHB and HCC patients (68.7% and 66.6% respectively) ( Fig. 1 ). In the rest of the extracts, the dominant proportion of HBV DNA was found to be defective HBV DNA, lacking detectable HBx genetic region.
Phylogenetic analysis, genotypes and subgenotypes
The phylogenetic analysis (Fig. 2) of the 48 X gene sequences along with GenBank reference sequences showed seven distinct clusters corresponding to the HBV genotypes (A-D and F-H), however genotype E, clustered with the genotype D sequences. Among the 48 sequences generated in this study, genotype D (43.7%) was most frequently detected followed by genotype A (37.5%) and genotype C (18.7%). The genotypes determined with HBx sequences in this study matched exactly with RFLP patterns obtained with surface gene region sequences (data not shown). No recombinants were observed in this study. Among the isolates from the present study, all the 18 genotype A isolates clustered with reference subgenotype Aa/A1 clade, all the 9 genotype C isolates clustered with subgenotype Cs/C1 clade. However, 21 genotype D isolates showed the most diverse topology, clustering with clade corresponding to subgenotypes D1 (4 isolates), D2 (3 isolates), D3 (10 isolates) and D5 (4 isolates) ( Fig. 2 ).
Inter-genotypic and inter-subgenotypic divergence
The phylogenetic clusters observed with the X gene region in this study exactly matched with previously described genotype/subgenotype clusters obtained with whole genome sequences (Norder et al., 2004) . This suggested a high inter-and intra-genotypic variation in the 465 nt encoding the X gene region, comparable to that in the full genome of HBV. The mean inter-genotypic distances at the nucleotide level and amino acid level are shown in Table 1 . The mean intersubgenotypic distance among the subgenotypes of genotype A, B, C, D and F in the full-length X gene, and its two distinct functional domains (N-terminal and C-terminal) are shown in the Table 2 . Comparison of the consensus of reference subgenotype sequences showed a high divergence at both the nucleotide and amino acid level, intergenotypically and inter-subgenotypically. However the N-terminal showed an exceptionally high sequence divergence, compared to the C-terminal, indicating an exceptionally high type specific variability in the N-terminal domain.
Genotype specific residues
Comparison of the consensus sequences, calculation of d N and d S at each codon position indicated the amino acid positions that were significantly different among the consensus sequences, representing genotype specific residues (Fig. 3 ). These predicted sites were further confirmed by manually comparing with the reference sequence from different countries, retrieved from the GenBank. As expected from the divergence data, most of the specific residues were located in the Nterminal (first 50 amino acids) compared to the C-terminal regions. Among the variable positions in the N-terminal domain, residues at 6, 12, 26, 30, 38, 40, and 42 were found to specify the genotypes and the rest of the positions were well conserved within subgenotype reference sequences. At the C-terminal, residues at 78, 91, 101, 102, 118 and 119 were shown to be genotype dependent ( Fig. 3) .
Genetic variability in the present sequences
Among the 48 HBx sequences generated in the present study, the mean similarity between the sequences (in percentage) at nucleotide level was 95.67 ± 0.015 and mean similarity between sequences (in percentage) at amino acid level was 92.92 ± 0.033.
Compared to the respective reference genotype consensus sequence, the variability in the sequences generated in the present study was determined. Sporadic mutations were observed at some sites, although in the majority, the sequences were similar to the consensus reference sequences, indicating low genetic variability in these samples. However region specific variability (substitution at a particular site in 50% or more of the isolates, compared to the corresponding consensus reference sequence) was observed in subgenotypes Aa/A1 (at positions 36, 88, 101), in Cs (at position 30), in D1 (in position at 47) and in D5 (at positions 41, 102 and 110) (Supplementary data 1). Compared to reference sequences, residues at 36, 88, 101 in Aa/A1 and residues 41, 110 in D5 were found to be specific signature residues (prevalence N70%) in HBV strains circulating in our population.
For documenting the clinically relevant mutations, changes at residue positions, other than the genotype specific sites were documented (Supplementary data 2). A total of 29 residue positions were found to have different substitutions in different clinical categories. However, no specific substitutions corresponding to any particular clinical outcomes were documented. Leucine (L) at HBx residue position 5 was found in all our sequences. Residue A 31 was detected in all but one subgenotype Aa/A1 sequences. Residue S 38 was detected in only 2 subgenotype Cs/C1 samples. Substitution Y 94 was detected in 2 samples, one each of subgenotype Cs/C1 and D5. Residue P 101 was detected in 4 samples only from subgenotype Aa/A1. Interestingly, substitution at position 127, 130 and 131 was present in all the clinical categories. However, the occurrence of these mutations were higher in genotypes A (66.7%), C (91%) and subgenotype D5 (75%). Notably, in all but one case, mutation at position 127 was always present with M 130 and I 131 . Compared to IC group, prevalence of M 130 and I 131 was significantly higher among CHB patients (36% vs. 55%, P = 0.010) and HCC patients (36% vs. 100%, P b 0.001). No insertions or deletions were observed, although a premature stop codon appeared at position 104 in only one subgenotype Cs/C1 isolate, predicting deletion of 50 C-terminal amino acids.
Predicted characteristics of HBx protein
The PROSITE motif search program identified Protein kinase C (PKC) phosphorylation site at positions 11, 54, 75 and Casein kinase II (CK II) phosphorylation site at positions 11, 104. Interestingly, the PKC and CK II phosphorylation sites in the HBx C-terminal (at sites 54, 75 and 104) are well conserved among all the genotypes. One PKC site (S 11 SR) in the N-terminal was present only in Aa/A1 and Ac/A3, while subgenotype Ae/2 had P 11 SR. The rest of the other genotypes had either P 11 TR or P 11 AR.
The HBx protein was predicted to be a compact globular domain (with 91 residues predicted to be exposed) by the GLOBE program. The results of the prediction of helix, extended sheet and coiled loop by PHD and PROF programs are presented in Supplementary data 3. The random coiled structure was observed in the N-terminal region corresponding to the hypervariable region, while the helical structure was predicted in the C-terminal binding domains. Relative solvent accessibility (in 10 states) as predicted by PROFacc was found to be higher in residues corresponding to the hypervariable region of the Nterminal.
Discussion
Using an advanced algorithm for protein structure prediction, in contrast to a previous study (Colgrove et al., 1989) , we in this study detected non-alpha, non-sheeted, coiled-coil structure with relatively high solvent accessibility of the N-terminal residues, suggesting a dominant B-cell epitope region (Park et al., 2000) . Further analysis of the sequences of different HBV genotypes also showed that most of the type specific variability is concentrated in the N-terminal of the HBx. The presence of HBx genotype variability in the immunodominant region supports the role of immune selection in evolution of different HBV genotypes (Osiowy, 2006) . It is well known that the N-terminal domain of HBx is indispensable for dimerization, transforming activity, anchorage-independent proliferation activity, negative regulation of proapoptotic activity and can overcome oncogene induced senescence (OIS) (Bouchard and Schneider, 2004; Tang et al., 2006) . On the other hand, due to the overlap with several regulatory elements (Tang et al., 2006) , the C-terminal domain of HBx sequence and its functions are relatively well conserved (Schuster et al., 2002) . Taken together, it is evident from the present analysis that the HBx N-terminal domain and its variability is involved in significantly contributing to differential pathogenic potentials of HBV genotypes/subgenotypes, which clearly supports a recent study showing that effects of the same C-terminal HBx mutations are genotype differentiated (Lin et al., 2005) .
The present study reveals important facets of HBV genetic variability in our study population. The detection of DNase I sensitive The numbers indicate percentage differences in the nucleotide (nt, shown in bold) and deduced amino acid sequences (aa, shown in italics) of HBx. The numbers indicate percentage differences in the nucleotide (nt) and deduced amino acid sequences (aa) of full X ORF, the N-terminal and the C-terminal domains. HBV DNA in our study subjects is in accordance with a previous study (Cabrerizo et al., 1997) . Moreover, similar to the reports of the frequent loss of surface and polymerase genetic regions of HBV in other populations (Gunther et al., 1997) , the frequent loss of HBx genetic region appears to be a unique feature of HBV strains circulating in our population. The phenomenon of the detection of HBV genome lacking important HBV genetic regions has been suggested to occur due to splicing (Gunther et al., 1997; Lee et al., 2008) or due to the circulation of HBV DNA integrated in human chromosomes (Fleischhacker and Schmidt, 2007) . Recent studies have established that the HBx Cterminal domain exercises a proapoptotic activity to counter balance the proliferative and transforming activities of the HBx N-terminal domain (Tang et al., 2006) , which explains the frequent development of HCC in patients with truncation in the HBx C-terminal region (Tu et al., 2001; Liu et al., 2008) . On the other hand, the abundance of HBV DNA, lacking the entire HBx genetic region in this population and extremely low occurrence of solely C-terminal truncated HBV in our patients well correlate with low incidence of HCC in our population. Furthermore the higher prevalence of intact virion DNA, in CHB patients in this study underscores the importance of intact HBx in persistently inducing immune response leading to chronic liver injury (Bouchard and Schneider, 2004; Tang et al., 2006) . On the other hand, the higher prevalence of LC patients with HBV variants in our study clearly supports a recent finding that HBV variants with deletions are important in the pathogenesis of cirrhosis (Marschenz et al., 2006) . Thus, in addition to supporting previous findings, our study also discloses other interesting results, which encourages further investigations.
In this study, we detected three distinct HBV genotypes (A, C and D) from the phylogenetic analysis of the HBx gene sequences that confirmed our previous results (Banerjee et al., 2006a; Banerjee et al., 2006b) . The Eastern Indian population thus provides an opportunity to compare between three distinct HBV genotypes. Although due to the detection of a number of patients with defective HBV genome and low occurrence of HCC, we could study the variability of the HBx in a relatively small number of patients, but our analysis presents the very first picture of the HBx genetic variability patterns in a population of the Indian subcontinent.
In order to verify the clinical relevance of the mutations documented in this study, we collected the available literature focused on the functional significance of different HBx substitutions and sought their associations with genotypes/subgenotypes of HBV (Table 3 ). We noted that most of the HBx substitutions associated with severe liver disease, studied until now are either genotype specific or prevalent among certain genotypes only (Table 3 ) and involved a change from a hydrophilic to hydrophobic residue or vice versa at a particular site. This also suggests that a small number of substitutions emerging at particular positions in particular HBV genotypes/ subgenotypes may alter the local configuration of HBx, which might lead to altered functional properties of HBx. Moreover, the review of the literature on this particular aspect seem to indicate that clinically relevant substitutions may emerge differently in distinct populations even with the circulation of similar strains of HBV.
In a recent study on Korean patients (Kim et al., 2008) , where subgenotype Ce/C2 is prevalent, a particular mutation M/L 5 was found to be significantly associated with HCC development. In our analysis we observed that in HBx of subgenotype Ce/C2, the naturally occurring residue is V 5 , while in most other genotypes the naturally occurring residues are M/L 5 (Table 3 ) . Thus, in the Korean population, the substitution of the normal V 5 with M/L 5 appears to increase the risk for HCC development in subjects infected with Ce/C2. Similarly, in a previous study on Taiwan (Yeh et al., 2000) , the A 31 mutation of HBx was significantly associated with HCC. Interestingly, we detected a high prevalence of A 31 in non-HCC patients in our study population. (Noh et al., 2004) , and also interacts with Pin1, leading to HCC (Pang et al., 2007 (Poussin et al., 1999) . c Y 94genotype G
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High expression of p21, reduction of cell cycle and increased apoptosis (Kwun and Jang, 2004) .
Low expression of p21, increase in cell cycle and thus cell proliferation (Kwun and Jang, 2004) .
Strong inhibitor of p21, increased cell proliferation (Kwun and Jang, 2004) . 1762 T prevent binding of LEF e , suppress only preC mRNA (HBeAg expression), enhance progeny virus synthesis (Kramvis and Kew, 1999) . d K 130 → c M 130 a mutation frequent in HCC patients, infected with genotypes A and C (Kramvis and Kew, 1999) .
C T 127
These residues affect antiproliferative activity (Lin et al., 2005) . The nucleotides enhance viral replication due to a change in pgRNA stem loop structure. The contribution of mutation at 1764 A is low compared to 1762 T (Kramvis and Kew, 1999 Increases the anti-proliferative activity of HBx of genotype B, but not in genotype C (Lin et al., 2005) .
The genotype/subgenotype specificity of these mutations is also presented. Our analysis revealed that A 31 is specific for subgenotype Aa/A1. Moreover examination of genotype specific residues, as reported by Kidd-Ljunggren et al. (1995) , we found that all the HBx sequences reported by Yeh et al. (2000) were of genotype A. Interestingly based on the analysis of surface gene region, prevalence of genotypes B and C in Taiwanese HCC patients (Kao, 2003) , while detection of genotype A specific HBx sequences by Yeh et al. (2000) seem to indicate that the prevalent strains of HBV in Taiwan might possibly be B/A, C/A recombinants, which might have higher oncogenic potentials. Thus the HBx with a A 31 substitution found in this study, is a part of the natural variability of non-recombinant genotype Aa/A1 strains in our population and was not associated with higher occurrence of HCC.
Recently, Muroyama et al. (2006) reported HBx substitution S 38 in genotype C to be significantly associated with HCC patients. However the association of S 38 with HCC remains unclear as in another recent study from the same country (Japan), such association with HCC was not documented (Shinkai et al., 2007) . Another residue, Y 94 , has been shown to induce clonal outgrowth of cells and inhibit apoptosis (Poussin et al., 1999) . The prevalence of these residues (S 38 and Y 94 ) was found to be very low in our study population. In addition, most of the present sequences had S 101 , which induces high expression of p21 (Kwun and Jang, 2004) , leading the reduced cell proliferation and increased apoptosis of the HBV infected cells.
In this study apart from genotype/subgenotype specific substitutions and some regional variability, the occurrence of sporadic mutation was also low, and mutations, insertions or deletions specific for any clinical outcome were not observed, similar to previous reports (Cabrerizo et al., 1998; Terada et al., 2001) . However, in accordance with published reports (Kim et al., 2008; Sung et al., 2008; Song et al., 2005; Iavarone et al., 2003) we also detected substitutions at 127, 130 and 131 residue positions among all the three genotypes, with significantly higher percentage among advanced liver disease patients, supporting the clinical importance of these mutations (Kim et al., 2008) . Although functional significance of the double mutations (M 130 and I 131 ) have been sought, the results are contradictory, with one report suggesting increased p21 repression activity (Kwun and Jang, 2004) while two others documenting no alteration in the transactivation function (Tu et al., 2001; Minemura et al., 2005) . Notably, these three studies were performed with HBV sequences isolated from patients from Korea (Kwun and Jang, 2004) , Japan (Minemura et al., 2005) and France/South Africa (Tu et al., 2001) , countries with different prevalence of HBV genotypes, indicating that the divergence in results may be due to genotype differentiated effects of these HBx mutations, clearly supporting a recent finding (Lin et al., 2005) . In our study, C-terminal truncation was predicted in only one non-HCC case, while in none of the HCC cases. This is in contrast to a recent study from China, reporting that HBx C-terminal deletions are frequent in both tumor and non-tumor tissues (Liu et al., 2008) . Taken together, it is evident from the present study that the variety of clinically relevant HBx mutation/deletion patterns may have their own prevalence and behavior in different geo-ethnic populations and the high incidence of HCC in certain populations may signify the presence of other risk factors, such as ethnicity, high dietary Aflatoxin B1 exposure etc.
Interestingly, molecular epidemiological studies have revealed that high incidences of HBV related HCC development in Sub-Saharan African or East Asian countries is strongly associated with codon 249 mutation of p53, known to be induced by HBx expression and high dietary exposure to Aflatoxin B1 (AFB1) (Hussain et al., 2007; Madden et al., 2002) . We would like to mention here that in a study on p53 mutations (Datta et al., unpublished data) , we could not detect the codon 249 mutation of p53 in any of our study population, which corroborate with a previous study (Katiyar et al., 2000) documenting very low prevalence of this particular HCC associated mutation in Northern Indian HCC patients, despite high Aspergillus contamination. Interestingly, among the daily Indian diets, turmeric (active ingredient 'Curcumin') is widely used (Sinha et al., 2003) , that has been shown to protects against AFB induced mutagenicity and hepatocarcinogenesis (Soni et al., 1997) . The preventive role of Indian spices and food additives in the low incidence of HCC and other forms of cancers thus needs further investigations.
In conclusion, compared to other regions of world with high HCC prevalence, Indian HBV isolates have very low prevalence of HBx mutations, absence of C-terminal deletions in HBx, and absence of p53 codon 249 mutations. Thus, our study shows that clinically important HBx mutations may emerge specifically in different HBV genotypes/ subgenotypes that might modulate different pathogenic pathways through complex interactions with different ethnic and environmental risk factors. Therefore the clinical significance of HBV genotypes and corresponding mutations in a given population may not be always relevant to another population, even if the prevalent viral strains are similar in both the population. Taken together, evaluation of HBx functions from the perspective of genetic variability and geo-ethnic factors are thus essential for a better understanding of HBV genotypephenotype relations. Further studies on HBx functions, from the perspective of genetic variability may help identify HBV genotype specific pathogenetic pathways, which are essential for the development of HBV genotype specific therapeutics to efficiently reduce the burden of HBV related liver complications.
Materials and methods
Study subjects
The present study was done on 102 sera from HBsAg positive, HBV surface gene PCR or HBV core gene PCR positive subjects who presented with different clinical manifestations. These patients were referred to our unit from different liver clinics, for detailed HBV DNA analysis. All the subjects were screened for HCV or HIV infection, chronic alcoholism or other concomitant causes of liver diseases, before including in the study. Of the sera included for X gene amplification, sequencing and analysis, 32 sera were from inactive carriers (IC), 32 were from chronic Hepatitis B (CHB) and 24 were from liver cirrhosis (LC) patients. Due to low incidence in this region, we could study sera from only 6 well diagnosed HCC cases. Sera from only 8 acute hepatitis B (ACU) patients, satisfying the study inclusion criteria were available for detailed analysis.
This work was the part of a study approved by the institutional Ethics Committee. Informed consent was obtained from the subjects or their guardians before blood collection.
Serological markers
Commercial ELISA based kits were used for HBsAg (Biomerieux, Boxtel, The Netherlands), HBeAg/anti-HBe (Biomerieux, and EQUIPAR, Soronno, Varese, Italy), anti-HCV (Ortho-Clinical Diagnostics, New Jersey, USA) and anti-HIV (Biomerieux) detection. ALT was estimated by Ecoline ALAT kit (Merck Specialties, Mumbai, India).
DNA extraction, amplification and sequencing
HBV DNA was extracted from serum by Proteinase K-Phenol/ chloroform method. Amplification of the partial promoter region of the human interleukin-1β gene was done for verification of the DNA extraction procedure and HBV DNA was initially detected by in-house nested HBV surface or precore/core gene amplification PCRs. Strict precautions were followed to avoid cross contamination and appropriate negative and positive controls were included during DNA extraction and PCR amplification steps. HBV X gene region was amplified by a hotstart PCR protocol (AmpliTaq Gold DNA polymerase, Applied Biosystems, Foster City, CA, USA), and the primers HBx1093F [5′-actttctcgccaacttacaaggccttt-3′ (1092-1118)] and HBx1977R [5′-gaaggaaagaagtcagaaggcaa-3′ (1972-1950) ] for first round amplification, and primers HBx1265F [5′-gccgatccatactgcggaactc-3′(1259-1280)] and HBx1887R [5′ccaaggcacagcttggaggct-3′(1885-1865)] for nested amplification of the full X genetic region. The primers were specifically designed to anneal to highly conserved regions of the HBV genome. In addition to these primer sets, previously published primers (Kidd-Ljunggren et al., 1995) for the amplification of partial X gene fragments were also used, where full X gene amplification could not be obtained by the above mentioned PCR. PCR amplified products were purified (Qiagen GmbH, Hilden, Germany) and directly sequenced using a Prism Big Dye 3.0 Kit and ABI 3100 automated DNA sequencer (Applied Biosystems, Foster City, CA, USA).
Detection of circulating virion free HBV DNA
Although all the sera samples included in this study had HBV surface gene sequences amplifiable by nested PCR, HBV X gene sequences could not be amplifiable in a number of these samples, despite similar amplification efficiencies of both the PCR assays. This observation prompted us to probe for the presence of DNase I sensitive HBV genomes in these cases. To distinguish between DNase I sensitive HBV DNA and virions associated intact HBV DNA, 400 μl of sera samples were divided into two parts. One part was digested with DNase I (New England Biolabs, Beverly, USA) at 37°C for 30 min following an earlier described method (Cabrerizo et al., 1997) . The DNase I digested and undigested parts of each serum sample were then subjected to DNA extraction, and amplification by nested PCR assays as described previously.
Molecular evolutionary analyses
All the HBx sequences generated in this study were edited manually by visual inspection and were multiply aligned with reference full genome HBV sequences (retrieved from the GenBank) of different genotypes and subgenotypes (Norder et al., 2004) , using ClustalW program incorporated in Bioedit version 7.0 (Hall, 1999) . Genetic distances were estimated by Kimura's two-parameter method and the phylogenetic tree was constructed by the neighbor-joining (NJ) method. The reliability of the pairwise comparison and phylogenetic tree analysis was assessed by bootstrap resampling with 1000 replicates. Phylogenetic and molecular evolutionary analyses were done using MEGA version 3.0 (Kumar et al., 2004) .
Consensus sequences, rate of non-synonymous (d N ), synonymous (d S ) substitutions and signature amino acid patterns
To determine the consensus sequences, 114 full-length GenBank sequences belonging to different HBV genotypes/subgenotypes, and submitted from different countries were retrieved analyzed and used for comparison of the sequences generated in the present study. Consensus sequences of different genotypes were aligned, codon-wise d N , d S were calculated and compared to determine the residues that were significantly different among genotypes. Codon-wise d N , d S between the consensus sequences and signature amino acid patterns were calculated using sequence analysis tools -CONSENSUS, SNAP (Nei and Gojobori, 1986) and VESPA (Korber and Myers, 1992) respectively, available at the Los Alamos National Laboratory website (http://hcv.lanl.gov/).
Prediction of structural characteristics of HBx
To identify potential antigenic sites of HBx, hydrophobicity profile was created employing the Kyte and Doolittle (1982) method, implemented in Bioedit version 7.0. Predictions of different structural characteristics of HBx were done, utilizing the PredictProtein server (Rost et al., 2004; http://www.predictprotein.org/) .
Statistical comparisons
Statistical differences were calculated using the χ 2 test or Fisher's exact probability test and Student's t-test where applicable. Two tailed P values ≤ 0.05 were considered statistically significant. For statistical calculations, Microsoft Office Excel (Microsoft Corporation, USA) or StatCalc (EpiInfo, version 6.0, CDC, USA and WHO, Switzerland) were used.
GenBank accession numbers
The GenBank accession numbers of Eastern Indian HBV X gene sequences analyzed in this study are EF594748 through EF594786 and DQ315776 through DQ315786.
